시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계 암 단클론항체 시장 보고서(2024년)
Cancer Monoclonal Antibodies Global Market Report 2024
상품코드 : 1429357
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,000 ￦ 7,161,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,500 ￦ 10,741,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,000 ￦ 14,322,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

암 단클론항체 시장 규모는 향후 수년간 대폭적인 성장이 예상되고 있습니다. 2028년 복합 연간 성장률(CAGR) 9.8%를 나타낼 전망이며 959억 9,000만 달러로 성장할 것으로 예상되고 있습니다. 예측기간 동안 예상되는 성장은 암 유병률 증가, 세계 접근의 확대, 헬스케어 지출 증가에 의해 추진됩니다. 주요 동향은 전략적 협업을 통한 제품 혁신, 기술 진보, 인간화 된 암 모노클로 날 항체 개발, 연구 개발 비용 절감 및 의약품 개발 촉진을위한 AI 투자, 연구 개발 투자 증가 등이 포함됩니다.

세계 암 이환율의 급증은 암 단클론항체 시장의 확대에 크게 공헌하려고 하고 있습니다. 예를 들어 미국암협회의 데이터에 따르면 2022년 1월에는 미국에서만 약 190만명이 새롭게 암으로 진단되어 추정 60만9,360명의 암 관련 사망이 예측되고 있으며, 는 매일 약 1,670명의 사망자에 해당합니다. 세계적으로는 폐암, 전립선암, 장암, 여성 유방암의 4개의 가장 이환율이 높은 암이, 신규 암 증례 전체의 43%를 차지하고 있습니다. 그 결과, 세계 규모에서의 암 이환율의 상승에 의해 암 단클론항체 시장 수요가 높아질 것으로 예상됩니다.

암 단클론항체 시장의 예상 성장은 헬스케어 지출의 급증에 의해 더욱 가속됩니다. 건강 관리 지출에는 개인, 지역사회, 국가, 세계 수준에 관계없이 특정 기간 동안 의료 관련 서비스, 제품 및 노력에 할당된 총 금액이 포함됩니다. 헬스케어 분야에 대한 투자가 증가함에 따라 단클론항체 치료에 대한 개발, 접근성 및 조사가 크게 강화될 수 있습니다. 또한, 이러한 투자는 이러한 치료법의 제조와 제공에 있어서 최첨단 기술의 통합을 촉진합니다. 특히 국가 통계국은 2023년 5월 영국의 건강 관리 지출이 명목 9.4% 증가, 실질 9.7% 증가와 현저한 증가를 경험했다고 보고했습니다. 2021년 영국의 건강 관리 지출 총액은 3,672억 5,000만 달러(2,807억 파운드)에 이르렀고, 의약품 지출은 518억 4,000만 달러(396억 파운드)에 이르렀습니다. 게다가 예방의료 지출은 2021년 459억 3,000만 달러(351억 파운드)로 급증해 전년의 2배 이상이 되었습니다. 따라서 건강 관리의 상승은 가까운 미래에 암 단클론항체 시장의 성장 궤도를 추진하는 주요 원동력이 될 것으로 예상됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

제5장 세계 시장 규모와 성장

제6장 시장 세분화

제7장 지역 및 국가 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 선도적이고 혁신적인 기업

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병(M&A)

제35장 미래 전망과 가능성 분석

제36장 부록

BJH
영문 목차

영문목차

Cancer monoclonal antibodies are lab-created proteins designed to bind to specific targets, such as antigens on cancer cells. Each antibody is tailored to bind to a single antigen, resulting in a diverse range of monoclonal antibodies.

Key types of monoclonal antibody therapies for cancer include bevacizumab (Avastin), rituximab (Rituxan), trastuzumab (Herceptin), cetuximab (Erbitux), and panitumumab (Vectibix). Avastin, for example, is utilized for treating wet age-related macular degeneration and diabetic eye problems. Applications span breast cancer, blood cancer, liver cancer, brain cancer, colorectal cancer, and more. These therapies are utilized across various sectors, including hospitals, clinics, research laboratories, pharmacies, and others.

The cancer monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides cancer monoclonal antibodies market statistics, such as cancer monoclonal antibodies industry global market size, regional shares, competitors with a cancer monoclonal antibodies market share, detailed cancer monoclonal antibodies market segments, market trends and opportunities, and any other information you may require to thrive in the ca This cancer monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cancer monoclonal antibodies market size has grown rapidly in recent years. It will grow from $59.98 billion in 2023 to $66.1 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The historical growth can be attributed to the growth of emerging markets, a rise in research and development (R&D) expenditure, an increased geriatric population, and a growing preference for biological treatments.

The cancer monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $95.99 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. Anticipated growth in the forecast period is driven by the increasing prevalence of cancer, expanding global access, and a rise in healthcare expenditure. Key trends include product innovation through strategic collaborations, technological advancements, the development of humanized cancer monoclonal antibodies, investments in AI to reduce R&D costs and expedite drug development, and increased R&D investments.

The surge in cancer incidences worldwide is poised to significantly contribute to the expansion of the cancer monoclonal antibody market. For instance, data from the American Cancer Society projected approximately 1.9 million new cancer diagnoses and an estimated 609,360 cancer-related deaths in the United States alone in January 2022, translating to roughly 1,670 fatalities daily. Globally, the four most prevalent cancer types - lung, prostate, bowel, and female breast cancer - collectively account for 43 percent of all new cancer cases. Consequently, the escalating rates of cancer incidence on a global scale are expected to drive heightened demand within the cancer monoclonal antibody market.

The anticipated growth of the Cancer Monoclonal Antibodies market is further fueled by an upsurge in healthcare expenditures. Healthcare expenditures encompass the aggregate amount allocated toward healthcare-related services, products, and endeavors over a specified period, whether at an individual, community, national, or global level. Increased investment in healthcare sectors can substantially bolster the development, accessibility, and research pertaining to monoclonal antibody treatments. Moreover, such investments facilitate the integration of cutting-edge technologies in the production and delivery of these treatments. Notably, the Office for National Statistics reported in May 2023 that healthcare spending in the UK experienced a notable upswing, with a nominal increase of 9.4% and a real increase of 9.7%. In 2021, the UK's total healthcare expenditure amounted to $367.25 billion (£280.7 billion), with pharmaceutical expenditure reaching $51.84 billion (£39.6 billion). Additionally, preventive care spending surged to $45.93 billion (£35.1 billion) in 2021, more than doubling from the previous year. Consequently, the escalating healthcare expenditure landscape is expected to be a key driver propelling the growth trajectory of the cancer monoclonal antibodies market in the foreseeable future.

Companies within the cancer monoclonal antibody market are actively pursuing product innovation through strategic collaborations as a means to sustain competitiveness in the industry. To navigate the increasingly competitive landscape, these companies are not only focusing on developing innovative products but also engaging in partnerships aimed at sharing skills and expertise. While partnerships with academic and research institutions have been a traditional practice in this sector, the trend of collaboration has notably intensified in recent years. As an illustration, in March 2023, BioNTech SE, a German biotechnology research company, entered into a partnership with OncoC4, Inc. This collaboration aims to jointly develop and commercialize an innovative checkpoint antibody targeting various solid tumor indications. BioNTech will gain an exclusive worldwide license for the ONC-392 anti-CTLA-4 monoclonal antibody from OncoC4. The partnership outlines plans for joint development in solid tumor indications, including the initiation of a Phase 3 trial in 2023. Additionally, BioNTech will explore combination therapies and provide a $200 million upfront payment, alongside royalty payments, and potential milestone payments to OncoC4. OncoC4, Inc., based in the US, specializes in the clinical-stage development of biopharmaceuticals for cancer treatment.

Companies are directing their efforts toward pioneering biologic therapies, such as EPKINLY, to reinforce their market position. EPKINLY stands as an FDA-approved bispecific antibody designed for the treatment of advanced lymphoma. In a significant development in May 2023, AbbVie Inc., a US-based biopharmaceutical company, secured approval from the U.S. Food and Drug Administration (FDA) for EPKINLYTM (epcoritamab-bysp). This groundbreaking approval marks EPKINLY as the first and sole T-cell engaging bispecific antibody designated for treating adult patients grappling with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including instances originating from indolent lymphoma, and high-grade B-cell lymphoma (HGBL) who have undergone at least two rounds of systemic therapies.

In November 2021, Pfizer Inc., a U.S.-based pharmaceutical and biotechnology company, successfully acquired Trillium Therapeutics for $2.22 billion. This strategic acquisition is geared towards expanding Pfizer's portfolio of biologics that boost the innate immune system, targeting both hematological malignancies and solid tumors. Trillium Therapeutics, headquartered in Canada, specializes in the development of innovative immunotherapies and antibody programs for cancer treatment.

Major companies operating in the cancer monoclonal antibodies market report are F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol Myers Squibb Company, Johnson & Johnson, Amgen Inc., AstraZeneca PLC, Eli Lilly and Company, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A, Innovent Biologics, Sino biological, Shanghai Henlius Biotech, Intas bio, Zydus Cadila, Ranbaxy, Takeda pharmaceuticals, AbbVie Inc., Biogen Idec, Bayer AG, Novartis AG, BiosanaPharma, WuXi, GlaxoSmithKline, Teva UK Limited, Abbott Laboratories, Fujifilm, Procos SpA, BSP Pharmaceuticals, Genmab, Insysbio, Rani Therapeutics, Emisphere Technologies, Inc., Enteris BioPharma, Allena Pharmaceuticals, Apotex, Gilead Sciences, Eurofarma, Teuto Brasileiro, BioMarin Pharmaceutical, BIONOVIS BRASIL, Ecopharm, Hypermarcas, Ache, Libbs Farmaceutica, Julphar, Spimaco Addwaeih, Hikma Pharmaceuticals, Tabuk, Novo Nordisk, BBI Solutions, APC Pharma, EPICIO, Medical Union Pharmaceuticals, South Egypt Drug Industries Co. Pharmaceutical, Vacsera Pharma, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd., 54gene, Baxter International, Altis Biologics, Cipla Medpro South Africa, Genzyme

North America was the largest region in the cancer monoclonal antibodies market in 2023. The regions covered in the cancer monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the cancer monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The cancer monoclonal antibody market consists of sales of pembrolizumab, blinatumomab, casirivimab, and imdevimab. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Monoclonal Antibodies Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cancer monoclonal antibodies? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer monoclonal antibodies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Scope

Markets Covered:

Table of Contents

1. Executive Summary

2. Cancer Monoclonal Antibodies Market Characteristics

3. Cancer Monoclonal Antibodies Market Trends And Strategies

4. Cancer Monoclonal Antibodies Market - Macro Economic Scenario

5. Global Cancer Monoclonal Antibodies Market Size and Growth

6. Cancer Monoclonal Antibodies Market Segmentation

7. Cancer Monoclonal Antibodies Market Regional And Country Analysis

8. Asia-Pacific Cancer Monoclonal Antibodies Market

9. China Cancer Monoclonal Antibodies Market

10. India Cancer Monoclonal Antibodies Market

11. Japan Cancer Monoclonal Antibodies Market

12. Australia Cancer Monoclonal Antibodies Market

13. Indonesia Cancer Monoclonal Antibodies Market

14. South Korea Cancer Monoclonal Antibodies Market

15. Western Europe Cancer Monoclonal Antibodies Market

16. UK Cancer Monoclonal Antibodies Market

17. Germany Cancer Monoclonal Antibodies Market

18. France Cancer Monoclonal Antibodies Market

19. Italy Cancer Monoclonal Antibodies Market

20. Spain Cancer Monoclonal Antibodies Market

21. Eastern Europe Cancer Monoclonal Antibodies Market

22. Russia Cancer Monoclonal Antibodies Market

23. North America Cancer Monoclonal Antibodies Market

24. USA Cancer Monoclonal Antibodies Market

25. Canada Cancer Monoclonal Antibodies Market

26. South America Cancer Monoclonal Antibodies Market

27. Brazil Cancer Monoclonal Antibodies Market

28. Middle East Cancer Monoclonal Antibodies Market

29. Africa Cancer Monoclonal Antibodies Market

30. Cancer Monoclonal Antibodies Market Competitive Landscape And Company Profiles

31. Cancer Monoclonal Antibodies Market Other Major And Innovative Companies

32. Global Cancer Monoclonal Antibodies Market Competitive Benchmarking

33. Global Cancer Monoclonal Antibodies Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Cancer Monoclonal Antibodies Market

35. Cancer Monoclonal Antibodies Market Future Outlook and Potential Analysis

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기